Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoad-juvant phase II study (ABCSG 34).

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M.

EUR J CANCER. 2020; 132: 43-52.

https://pubmed.ncbi.nlm.nih.gov/32325419/